138 related articles for article (PubMed ID: 11388102)
1. Mechanisms of antiarrhythmic drug action on termination of atrial flutter.
Tai CT; Chen SA
Pacing Clin Electrophysiol; 2001 May; 24(5):824-34. PubMed ID: 11388102
[TBL] [Abstract][Full Text] [Related]
2. Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination.
Tai CT; Chen SA; Feng AN; Yu WC; Chen YJ; Chang MS
Circulation; 1998 May; 97(19):1935-45. PubMed ID: 9609087
[TBL] [Abstract][Full Text] [Related]
3. Dofetilide versus quinidine for atrial flutter: viva la difference!?
Olshansky B
J Cardiovasc Electrophysiol; 1996 Sep; 7(9):828-32. PubMed ID: 8884511
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy.
Cha Y; Wales A; Wolf P; Shahrokni S; Sawhney N; Feld GK
J Cardiovasc Electrophysiol; 1996 Sep; 7(9):809-27. PubMed ID: 8884510
[TBL] [Abstract][Full Text] [Related]
5. Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap.
Inoue H; Yamashita T; Nozaki A; Sugimoto T
J Am Coll Cardiol; 1991 Oct; 18(4):1098-104. PubMed ID: 1910060
[TBL] [Abstract][Full Text] [Related]
6. Characterization of low right atrial isthmus as the slow conduction zone and pharmacological target in typical atrial flutter.
Tai CT; Chen SA; Chiang CE; Lee SH; Ueng KC; Wen ZC; Huang JL; Chen YJ; Yu WC; Feng AN; Chiou CW; Chang MS
Circulation; 1997 Oct; 96(8):2601-11. PubMed ID: 9355900
[TBL] [Abstract][Full Text] [Related]
7. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug.
Crijns HJ; Van Gelder IC; Kingma JH; Dunselman PH; Gosselink AT; Lie KI
Eur Heart J; 1994 Oct; 15(10):1403-8. PubMed ID: 7821320
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing.
Stambler BS; Wood MA; Ellenbogen KA
Am J Cardiol; 1996 May; 77(11):960-6. PubMed ID: 8644646
[TBL] [Abstract][Full Text] [Related]
9. Antiarrhythmic drugs preferentially produce conduction block at the area of slow conduction in the re-entrant circuit of canine atrial flutter: comparative study of disopyramide, flecainide, and E-4031.
Inoue H; Yamashita T; Usui M; Nozaki A; Sugimoto T
Cardiovasc Res; 1991 Mar; 25(3):223-9. PubMed ID: 1903082
[TBL] [Abstract][Full Text] [Related]
10. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy.
Stambler BS; Wood MA; Ellenbogen KA
Circulation; 1997 Dec; 96(12):4298-306. PubMed ID: 9416896
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiology and pharmacology of ibutilide.
Naccarelli GV; Lee KS; Gibson JK; VanderLugt J
Am J Cardiol; 1996 Oct; 78(8A):12-6. PubMed ID: 8903270
[TBL] [Abstract][Full Text] [Related]
12. Dofetilide: a new pure class III antiarrhythmic agent.
Falk RH; Decara JM
Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
[TBL] [Abstract][Full Text] [Related]
13. Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation.
Foster RH; Wilde MI; Markham A
Drugs; 1997 Aug; 54(2):312-30. PubMed ID: 9257085
[TBL] [Abstract][Full Text] [Related]
14. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation.
Volgman AS; Carberry PA; Stambler B; Lewis WR; Dunn GH; Perry KT; Vanderlugt JT; Kowey PR
J Am Coll Cardiol; 1998 May; 31(6):1414-9. PubMed ID: 9581743
[TBL] [Abstract][Full Text] [Related]
15. Circus movement atrial flutter in the canine sterile pericarditis model. Differential effects of procainamide on the components of the reentrant pathway.
Schoels W; Yang H; Gough WB; el-Sherif N
Circ Res; 1991 Apr; 68(4):1117-26. PubMed ID: 2009611
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic alterations in human type I atrial flutter cycle length and monophasic action potential duration. Evidence of a fully excitable gap in the reentrant circuit.
Stambler BS; Wood MA; Ellenbogen KA
J Am Coll Cardiol; 1996 Feb; 27(2):453-61. PubMed ID: 8557920
[TBL] [Abstract][Full Text] [Related]
17. Effects of class IA antiarrhythmic drugs on the reentrant circuit in common human atrial flutter.
Ohga N; Inoue T; Doi T; Yoshida A; Yokoyama M
Jpn Circ J; 1995 Dec; 59(12):799-807. PubMed ID: 8788371
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiologic effects of SD-3212, a new class I antiarrhythmic drug, on canine atrial flutter and atrial action-potential characteristics.
Fujiki A; Tani M; Hayashi H; Mizumaki K; Inoue H; Uemura H; Nakaya H
J Cardiovasc Pharmacol; 1997 Apr; 29(4):471-5. PubMed ID: 9156356
[TBL] [Abstract][Full Text] [Related]
19. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
McClellan KJ; Markham A
Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.
Ellenbogen KA; Stambler BS; Wood MA; Sager PT; Wesley RC; Meissner MC; Zoble RG; Wakefield LK; Perry KT; Vanderlugt JT
J Am Coll Cardiol; 1996 Jul; 28(1):130-6. PubMed ID: 8752805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
